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Photoacoustic ratiometric assessment of mitoxantrone release 
from theranostic ICG-conjugated mesoporous silica nanoparticles  
Giuseppe Ferrauto,a† Fabio Carniato,b† Enza Di Gregorio,a Mauro Botta,b and Lorenzo Tei *b 
A theranostic nanosystem based on indocyanine green (ICG) 
covalently conjugated mesoporous silica nanoparticles (MSNs), 
loaded with the anticancer drug mitoxantrone (MTX) is proposed 
as innovative photoacoustic probe. Taking advantage from the 
characteristic PA signal displayed by both ICG and MTX, a PA-
ratiometric approach was applied to assess drug release profile 
from the MSNs. After a complete in vitro characterization of the 
nanoprobe, a proof-of-concept study has been carried out in 
tumour-bearing mice to evaluate in vivo its effectiveness for cancer 
imaging and chemotherapeutic agent delivery. 
Photoacoustic imaging (PAI) combines the properties of light 
and sound and it has recently emerged as a promising imaging 
modality with a wide range of possible applications in 
biomedicine.1 A typical PAI contrast agent is able to rapidly 
absorb light energy and generate heat, causing thermoelastic 
expansion and triggering the emission of ultrasound (US) 
waves,2-5 detectable by US transducers. High sensitivity 
exogenous imaging agents have been exploited to enhance the 
imaging signal.6 These consist of molecules with strong 
absorption in the near-infrared (NIR) region (=700 nm–1 m), 
since at these frequencies the optical attenuation is weaker and 
a deeper tissue penetration can be achieved. 
Among the NIR probes, ICG is one of the most employed for PAI 
applications because it is already FDA approved for human 
diagnosis and it has a good safety profile.7 However, its in vivo 
use is hampered by two important issues, i.e. i) ICG is strongly 
sequestered by Human Serum Albumin (HSA),8 with a 
consequent removal from the nanoprobe and ii) the 
photobleaching of ICG due to interaction with micro-
environmental species (e.g. O2 and water of tissues).7 The 
encapsulation of ICG inside nanocarriers (liposomes, micelles, 
lipidots, SWCN, etc…) has been exploited to enhance 
photostability of the molecule and prevent HSA binding,9-14 
although a competition study with HSA is often omitted. 
Notably, we have recently shown that the encapsulation of ICG 
into MSNs pores increases the photoacoustic effect of ca. 400% 
with respect to free ICG.15 This is due to fluorescence quenching 
and high photothermal conversion of the encapsulated dyes. 
The limitation of this approach is that HSA normally present in 
serum can sequester the dye, which is entrapped, but not 
blocked, inside the pores.  
In addition, PAI shows a great potential in the imaging-guided 
drug delivery field, allowing noninvasive monitoring of 
pharmacological treatments using non-ionizing radiations. 
MSNs are among the nanocarriers most used in drug delivery, 
due to the presence of drug loadable uniform mesopores, in 
addition to  their easy chemical functionalization and good 
biocompatibility.16 Recently, they have been employed to 
develop theranostic nanoprobes tested for single- or multi-
modality imaging approaches.17-20 At the best of our knowledge, 
only few examples of theranostic PAI probes have been 
reported.21 Overall, they are based on the co-loading of a PAI-
active dye and the therapeutic drug in the same nanocarrier.22 
Therefore, the release of the drug can be indirectly deduced by 
looking at the release of the PAI-active dye. However, the 
assumption of analogous biodistribution and release profile of 
the two molecules from the nanocarrier in vivo might be not 
always true. 
The possibility to detect directly the drug by PAI is challenging. 
Such ideal nanosystem should contain a covalently bound PAI-
active dye and a loaded chemotherapeutic agent, which is also 
detectable by PAI. Therefore, the aim of the present work was 
to design a theranostic nanoprobe in which drug delivery and 
release could be directly monitored by using PAI. In this way, 
two distinct PAI signals are expected to be generated, one 
reporting on the nanocarrier distribution and the other one 
reporting on the drug release. In light of the considerations 
reported above, MSNs were chosen as suitable nanocarrier, ICG 
dye was covalently conjugated to the MSNs and the drug 
mitoxantrone (MTX) was adsorbed on the surface. MTX, an 
anthraquinone derivative extensively investigated for the 
treatment of breast and prostate cancer,23 absorbs light in the 
NIR range24 and its detection using optical imaging has been 
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described. Nevertheless, to the best of knowledge, the direct 













Scheme 1.  Schematic illustration of the theranostic MTX-ICG-MSN 
photoacoustic nanoprobe. 
The structure of the nanosystem developed in this work is 
reported in Scheme 1. Beside ICG and MTX, MSNs surface has 
been also functionalized with PEG3000-COOH molecules to limit 
particles aggregation when dispersed in water and to stabilize 
the final suspension. Briefly, MSNs were prepared by 
surfactant-assisted sol-gel procedure25 that allows to obtain 
porous silica with particles size in the 25-50 nm range with an 
ordered mesopores architecture as shown by HRTEM and XRD 
analyses (Figure S1). MSNs were then functionalized with 
aminopropyl triethoxysilane followed by amide coupling of 
PEG3000-COOH molecules to the NH2 groups on the surface as 
verified by IR spectra before and after functionalization 
(Scheme S1 and Figure S2). The textural properties of MSNs, 
before and after functionalization, were also investigated by N2 
physisorption analysis (Figure S3) showing a decrease of both 
specific surface area and pore diameter due to the presence of 
the organic groups located inside the pores or on the channels 
entrance. The hydrodynamic diameter of PEG-NH2-MSN, 
homogeneously dispersed in water at room temperature and 
neutral pH, is ca. 120 nm with a polydispersity index of 0.42 
(Figure S4). The charge density exposed on the surface, 
calculated by ζ-potential, is +14.2 mV, because of the residual 
presence of NH2 groups (NH3+ at neutral pH) not involved in the 
coupling reaction with PEG molecules.  
Then, NHS-activated ICG molecules were attached to the 
residual amino groups exposed on the silica surface of PEG-NH2-
MSN. This strategy, compared to the simple impregnation 
previously adopted for the preparation of ICG-based MSNs,15 
increases the chemical stability of the probe preventing release 
in biological fluids. The material was finally impregnated with 
MTX in methanol, to obtain the final theranostic probe (MTX-
ICG-MSN). Other two materials based on pegylated silica, 
functionalized with ICG (ICG-MSN) or loaded with mitoxantrone 
(MTX-MSN) were also prepared as reference samples. The 
amount of ICG attached to the silica surface and of MTX loaded 
on MSNs were quantified via UV-Vis analysis as 0.3 and 38 μmol 
g-1, respectively.  
The photophysical properties of the nanoprobes were 
investigated in water solution by UV-Visible and 
photoluminescence spectroscopy. Figure 1 shows the UV-vis 
spectra of MTX-ICG-MSN in comparison to pure ICG-NHS in 
water at the same dye concentration (0.15 μM). An absorption 
at 790 nm assigned to the π → π* transitions is observed, 
slightly shifted to higher wavelengths with respect to the pure 
ICG dye, as a consequence of a different chemical environment. 
Furthermore, two other important bands at 609 and 661 nm are 
also observed and attributed to the π → π* electronic 
transitions of MTX drug (Figure 1A).24 The same two bands are 
clearly visible in the UV-Visible spectrum of MTX (Fig. 1A) and 









Figure 1. (A) UV-Visible spectra in aqueous solution at neutral pH of ICG-NHS 
(a), MTX-ICG-MSN (b) and MTX (c) ([ICG] = 0.15 μM; [MTX] = 11.2 μM); (B) 
Photoluminescence spectra of ICG-NHS (a), ICG-MSNs (b) and MTX-ICG-MSNs 
(c) in aqueous solution at neutral pH under excitation at 790 nm. 
The excitation of the sample at 790 nm promotes an intense 
emission centred at 810 nm in aqueous solution. The intensity 
of this peak was compared to that detected for pure ICG and 
ICG-MSN in water at the same dye concentration (0.15 μM) 
(Figure 1B). Anchoring the dye to the silica surface favoured an 
enhancement of the quantum yield, from 2.6% for ICG-NHS to 
3.4% and 5.0% for MTX-ICG-MSN and ICG-MSN samples, 
respectively (see ESI). Furthermore, MTX is characterized by an 
intrinsic photoluminescence emission when opportunely 
excited. Indeed, MTX-ICG-MSNs under excitation at 660 nm (at 
the maximum absorption of the drug) shows, along with the 
emission band at 810 nm, another peak at 680 nm attributed to 
the electronic transitions of MTX (Figure S6).  
In opposite to what observed for impregnated silica with ICG,15 
the chemical conjugation of the dye to the nanoparticles 
improves the photoluminescence efficiency of ICG and 
enhances the chemical stability of the probe. In fact, the 
analysis of the stability of the ICG-conjugated MSNs in 
reconstituted human serum (Seronorm™) showed no change in 
UV-vis spectrum over several hours (Figure S7). Conversely, the 
same test carried out on the ICG-impregnated MSNs sample 
previously reported,15 resulted in the release of the majority of 
ICG molecules after 1 h, due to the high affinity of ICG for HSA.   
Photoacoustic properties of MSNs samples were determined on 
a VisualSonics Vevo Imaging Station and the behaviour of MTX-
ICG-MSNs was compared to ICG-MSNs, MTX-MSNs and empty 
MSNs to assess the contribution of the different moieties to the 
photoacoustic spectrum (Figure 2). Empty PEG-NH2-MSNs are 
used as control as they do not display any PA signal. ICG-MSNs 
display a PA peak at 810 nm in analogy to literature data for 
both free ICG and ICG encapsulated inside MSNs pores.7, 15 On 
the other hand, MTX-MSNs show a PA peak at 700 nm 
characteristic of the free drug. With regard to the PA signal of 
ICG in MTX-ICG-MSNs particles (Figure S8), a slight  
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Figure 2. (A) US, (B) PAI at 700 nm, (C) PAI at 810 nm of a phantom 
containing tubes filled with different solutions and (D) comparison 
among PAI spectra of the four MSNs formulations; 1) ICG-MSNs 
([MSNs]=20mg/mL, [ICG]=6M, MTX=0) (red circles); 2) MTX-MSNs 
([MSNs]=12mg/mL, [ICG]=0, MTX=452M) (black squares); 3) MTX-ICG-
MSNs ([MSNs]=20mg/mL, [ICG]=6M, MTX=452 M) (blue triangles) 
and 4) PEG-NH2-MSNs ([MSNs]=20mg/mL, [ICG]=0, MTX=0)  (green 
diamonds). 
enhancement of PAI efficiency (ca. 75%) was observed with 
respect to free ICG. This enhancement is five times lower than 
that previously reported for ICG encapsulated inside MSNs’ 
pores (370%).15 On the other hand, PA efficiency of MTX is 2-3 
times higher when it is free in solution compared to the drug 
loaded MSNs (MTX-MSNs) (Figure S9 and Figure S10). Thus, 
MTX-ICG-MSNs display two PA signals, at 700 nm and 810 nm 
provided by the presence of MTX and ICG, respectively. At the 
best of our knowledge, this is the first time that the PA effect of 
MTX has been reported. This can be useful for both developing 
new PAI probes and for the PAI visualization of a 
chemotherapeutic agent distribution in vivo. Notably, the 
presence of two detectable PA signals in MTX-ICG-MSNs probe 
allowed us to determine the ratio between the intensities at 
700 and 810 nm that is expected to be constant at different 
probe concentrations, since it is simply due to the relative 
amount of ICG and MTX present in MSNs and their PA efficiency. 
Thus, this ratio was determined at variable concentration of 
MTX-ICG-MSNs (Figure S11) as 1.67 ± 0.15. It is not affected by 
the actual concentration of MSNs in the sample, but it is only 
related to the relative ICG/MTX amount in silica nanoparticles. 
This implies that the observation of the PA700nm/PA810nm ratio 
can be useful for assessing the amount of released MTX from 
MSNs, since the ratio should decrease with drug release.  
The percentage of drug release was assessed both by using UV-
vis spectrophotometry and by using PAI. UV-vis experiment was 
carried out in phosphate-buffered saline (PBS) at 25°C. In the 
case of MTX-MSNs, the drug release during the first 300 min 
followed a linear behaviour, typical of samples containing drugs 
strongly interacting with the surface.26 After 15 h, the release 
process reaches a plateau corresponding to a value of ca. 70% 
(Figure 3A). On the other hand, MTX release appears slower and 
reduced for MTX-ICG-MSNs. At end of the experiment, 20% of 
drug is released in PBS solution. The higher retention of MTX in 
MSNs having ICG conjugated on the surface is probably due 
both to the steric hindrance and non-covalent interactions with 
the fluorescent dye (Figure 3A).  
Then, MTX release was also assessed by using PAI by means of 
two different approaches. In the first experiment, MTX-ICG-
MSNs or MTX-MSNs were dispersed in water at the final 
concentration of 8 mg/mL and placed at 25°C. At variable time 
points (from 5 min to 48h), samples were centrifuged, and an 
aliquot of supernatant was collected for PAI analysis and 
substituted with fresh one. PA images at 700 nm and 810 nm of 
all collected samples were acquired. No ICG signal (PAI at 810 
nm) is present for all the analysed samples (data not shown), 
because ICG is covalently bound to MSNs and all nanoparticles 
were precipitated by centrifugation. MTX signal (PAI at 700nm) 
is present in all collected supernatants, especially in 
supernatants derived from MTX-MSNs (Figure 3B-D and Figure 
S12). In supernatants derived from MTX-ICG-MSNs, the amount 
of released MTX is lower and a slower drug release kinetic is 
observed, in analogy to the release tests reported above. 
Analogous results were reported for MSNs dispersed in serum, 
with a slightly faster kinetic of MTX release, probably because 
of the presence of HSA, which could partly sequester the drug. 
 
Figure 3: (A) Drug released from MTX-MSN (a) and MTX-ICG-MSNs (b) in PBS 
solution at 25°C assessed by UV-vis spectroscopy; (B) PA signal intensity at 
700 nm for MTX-MSNs (blue squares) or MTX-ICG-MSNs (blue triangle) at 
variable times; (C) PA spectra of MTX-MSNs’ supernatants and (D) PA spectra 
of MTX-ICG-MSNs’ supernatants. 
In the second experiment, MTX-ICG-MSNs were suspended in 
water or in serum and PA images (at 700 and 810 nm) were 
acquired at t=0. MSNs were then left at 25°C for 24h, 
centrifuged and re-suspended in fresh media. Then, PA image 
of samples were re- acquired. Figure 4A reports US and PA 
images at 700 nm and 810 nm at t=0 and t=24h. Figure 4B-C 
report PA spectra of both samples in water and serum, 
respectively. In both media, the PA signal at 810 nm do not vary 
from t=0 to t=24h, because the total amount of ICG conjugated 
to MSNs is not changed and its PA effect is maintained constant.  
Conversely, the signal at 700 nm, provided by MTX, is strongly 
reduced at 24h with respect to that at t=0. In particular, 
quantitative insights into the release of the drug can be gained 
by assessing the PA700nm/PA810nm ratio. In fact, this value is 
reduced from 1.66 to 0.67 when the release experiment was  
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Figure 4: (A) Representative US B-Mode image (left), PA image at 700 nm 
(middle) and PA image at 810 nm (right) of MTX-ICG-MSNs (8mg/mL) in water 
at t=0 (sample 1) and t=24h (sample 2); (B) PA spectra of MTX-ICG-MSNs 
(8mg/mL) in water at variable times (t=0, 30 min, 1h, 3h, 6h and 24h); (C) PA 
spectra of MTX-ICG-MSNs (8mg/mL) in serum at variable times (t=0, 30 min, 
1h, 3h, 6h and 24h); (D) PA signal intensity at 700 nm vs. time for MTX-ICG-
MSNs in water and in serum. 
  
carried out in water and from 1.79 to 0.69 in human serum, 
highlighting a substantial drug release from the MNSs. 
Finally, a preclinical study was performed to investigate the in 
vivo applicability of this probe for cancer theranostic studies. 
PAI evaluation of a syngeneic breast tumour murine model 
bearing subcutaneous TS/A mammary adenocarcinoma (US B-
mode image in Figure 5A, left column) was carried out in the 
680-980 nm wavelengths range at three time points: before 
(pre-contrast), immediately after (t=0) and 30 minutes away 
(t=30 min) (post-contrast) from i.v. injection of MTX-ICG-MSNs 
(dose of 120 mg MSNs/kg in 0.2 mL of volume). In pre-contrast 
PA images, endogenous haemoglobin (Hb) signal was visible at 
810 nm wavelength, including both the contribution of its 
oxygenated (oxy-Hb) and deoxygenated (deoxy-Hb) form. The 
presence of a significant amount of deoxygenated haemoglobin 
is typical of tumours at advanced development stages.27 In post-
contrast (t=0) PA image, the MTX-ICG-MSNs signal was 
detectable in the tumour region (Figure 5A, second line). In 
particular, it can be quantified in PA spectra inside a region of 
interest (ROI) manually drawing the tumour contour under US 
B-mode image guide. Interestingly, both PA signal of MTX 
(=700 nm) and ICG (=810 nm) were clearly distinguishable 
(Figure 5A-B). An enhancement of ca. 250% was revealed by 
measuring PA signal intensity at =700 nm and of ca. 135% by 
measuring PA signal at =810 nm (Figure 6A) compared to 
corresponding pre-contrast images. These findings suggest that 
this nanoprobe was able to improve tumour detection, and that 
MTX was successfully delivered in tumour lesion. 
Figure 5: (A) Representative US B-Mode image (left), PA image at 700 nm 
(middle) and PA image at 810 nm (right) of tumour in mouse leg pre contrast 
(first line) and post contrast at t=0 (second line) and t=30 min (third line). (B) 
PA spectra of ROIs indicated with white circles in (A) (N=3). 
Figure.6 (A) PA signal enhancement (%) and (B) PA700nm/PA810nm at t=0 and 
t=30 min after the injection of MTX-ICG-MSNs (120 mg/kg).  
 
In post-contrast (t=30min)  PA image (Figure 5A, third line), the 
signal of MTX resulted significantly decreased, with a ca. 64% 
enhancement measured at =700 nm with respect to pre-
contrast data (Figure 6A). On the contrary, PA signal of ICG at t= 
30 min post-injection shows ca. 83% enhancement with respect 
to pre-contrast image. It means that, from t=0 to t=30 min post- 
contrast administration, there is a remarkable reduction of MTX 
PA signal (contrast enhancement is reduced from 250% to 64%) 
and a much lower reduction of ICG PA signal (contrast 
enhancement is reduced from 135% to 83%) (Figure 6A).  
Overall, this in vivo release of MTX can be clearly highlighted by 
measuring the PA700nm/PA810nm ratio. This value is ca. 1.7 at t=0, 
in line with the one measured in vitro for MTX-ICG-MSNs (1.67 
± 0.15) and suggesting that in vivo, at t=0 time point, MTX would 
be retained in MSNs. On the contrary, at t=30 min time point, 
the PA700nm/PA810nm ratio decreases to 0.71, in agreement with 
the in vitro test of release discussed above (Figure 6B). This 
evidence supports the hypothesis that 30 minutes after in vivo 
MTX-ICG-MSNs administration, part of MTX could be released 
from MSNs. The kinetic of MTX release from nanocarrier and of 
the wash-out from the tumour region can be assessed by using 
this ratiometric PAI approach. 
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Conclusions 
An innovative theranostic nanosystem has been reported, 
based on the use of mesoporous silica nanoparticles covalently 
bound to ICG dye and impregnated with mitoxantrone, as 
chemotherapeutic agent. The covalent binding of ICG to the 
MSNs surface prevents the sequestration of ICG by serum 
albumin, thus increasing the ICG-MSNs stability with respect to 
the system in which ICG was loaded into MSNs pores. The 
presence of ICG on MSNs surface leads to a 75% enhancement 
of photoacoustic efficiency with respect to the free dye and 
reduces the release of MTX from ca. 60% to ca. 20%. 
MTX-ICG-MSNs exhibit interesting PAI properties since both ICG 
dye and MTX drug display evident and different PAI signals, at 
810 and 700 nm, respectively. Hence, the presence of one of the 
two molecules or both of them can be determined by acquiring 
PA images. The potential application of MTX-ICG-MSNs as 
theranostic nanoprobe in vivo was also assessed in a preclinical 
murine model of cancer, testing the feasibility for detect ICG 
and MTX signal in the tumour region by PAI. Moreover, the 
ratiometric measurement of the PA effect at 700 nm and at 810 
nm (PA700nm/PA810nm ratio) may allow the assessment of the 
drug release from the nanocarrier, and of the wash-out kinetics 
of both nanosystem and drug, as suggested by the significant 
reduction of MTX signal 30 minutes after MTX-ICG-MSNs 
administration. In fact, whereas immediately after MSNs 
injection both PA signals are present, after the signal of is 
significantly reduced and that of the ICG one, which resulted 
only marginally decreased at the same time point. 
In conclusion, the approach herein reported shows that i) 
theranostic MSN-based PAI nanosystems can be very useful for 
the simultaneous imaging and treatment of the tumour, ii) MTX 
can be detected and quantified in vivo by using PAI and iii) the 
assessment of PA700nm/PA810nm ratio can be useful to quantify 
the release of MTX from the nanoparticles. Thus, a new family 
of nanosized PA agents, suitable for theranostic applications can 
be further developed for in vivo applications. 
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